Q-omics provides the consensus-scored RPGRIP1L profile across patient tissues and cancer cell-line models. RPGRIP1L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPGRIP1L is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, RPGRIP1L RNA expression shows 20,853 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BLCA, COAD, and KIRP as cancer lineages where RPGRIP1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPGRIP1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPGRIP1L survival associations across molecular data types. RPGRIP1L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPGRIP1L RNA expression–survival associations across cancer types. High RPGRIP1L expression shows unfavorable associations in BLCA, STAD, LIHC, LGG, THCA and MESO. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RPGRIP1L RNA expression.
This table summarizes RPGRIP1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RPGRIP1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPGRIP1L shows higher tumor expression in COAD, KIRP, KIRC, LUAD, LIHC and BLCA. The COAD box plot shows higher RPGRIP1L RNA expression in tumor versus normal tissue (log2 FC = +0.958, t-test p < 0.001).
This table shows molecular features associated with RPGRIP1L in patient tissues and cancer cell lines. In patient samples, RPGRIP1L shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RPGRIP1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
